Vaccinex Shares Outstanding 2017-2021 | VCNX

Vaccinex shares outstanding from 2017 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Vaccinex Annual Shares Outstanding
(Millions of Shares)
2020 19
2019 13
2018 5
2017 1
2016 1
Vaccinex Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 29
2021-03-31 25
2020-12-31 19
2020-09-30 20
2020-06-30 17
2020-03-31 16
2019-12-31 13
2019-09-30 14
2019-06-30 11
2019-03-31 11
2018-12-31 5
2018-09-30 7
2018-06-30 1
2018-03-31 1
2017-12-31 1
2017-09-30 1
2017-06-30 1
2017-03-31 1
2016-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.056B $0.001B
Vaccinex, Inc. is a clinical-stage immunotherapy company. It engages in the discovery and development of biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune disorders. The company's product pipeline consists of VX15, VX5 and VX25 which are in clinical stage. Vaccinex, Inc. is based in Rochester, New York.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76